The earnings call presented a mix of positive financial performance with significant revenue growth and improved gross margins, alongside challenges related to safety concerns for IXCHIQ and an operating loss. The overall sentiment is balanced, reflecting both substantial achievements and notable challenges.

Company Guidance -

Q2 2025

During the first quarter of fiscal year 2025, Valneva reported a strong financial performance with total revenues reaching nearly €50 million, a 51.2% increase in product sales compared to the same period last year. Key achievements include a cash position exceeding €150 million, boosted by a €14.2 million ATM transaction in April, and significant progress in regulatory approvals for IXCHIQ, notably in the UK, Europe, and Brazil. The company highlighted the continuation of its Phase 3 Lyme disease study, VALOR, which involves over 9,000 participants and is expected to yield data by year-end, with potential regulatory filings anticipated next year. Valneva maintained its full-year guidance, projecting product sales between €170 million and €180 million, and total revenues of €180 million to €190 million. The company also reported an operating loss of €6 million for the quarter, compared to a profit of €68.2 million the previous year, largely due to a non-recurring revenue from a Priority Review Voucher sale in 2024. Looking forward, Valneva expects sustained profitability from 2027, contingent on Lyme disease vaccine approval and commercialization.

Strong Revenue Growth

Total revenues for Q1 2025 reached €49.2 million, a significant increase from €32.8 million in Q1 2024. Product sales rose by 51.2% year-over-year.

IXIARO Sales Increase

IXIARO sales reached €27.5 million, a 65.5% increase from the previous year, driven by strong sales to the US military and travel channels.

Improved Gross Margins

Gross margin on commercial products excluding IXCHIQ improved to 62.7% from 43.9% in Q1 2024, due to better manufacturing performance and fewer batch failures.

Regulatory Achievements

Valneva received marketing authorization for IXCHIQ in the UK, Europe, and Brazil, and submitted a label extension application for adolescents.

Lyme Disease Vaccine Progress

Progress in the Phase 3 study for the Lyme disease vaccine, VALOR, with expected data by the end of the year.

Valneva (VALN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VALN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-0.32 / -	-0.383	―	―	―
May 07, 2025	2025 (Q1)	-0.28 / -0.14	0.884	-115.84% (-1.02)
Mar 20, 2025	2024 (Q4)	-0.19 / -0.37	-0.509	28.09% (+0.14)
Nov 07, 2024	2024 (Q3)	-0.27 / -0.11	-0.537	79.52% (+0.43)
Aug 13, 2024	2024 (Q2)	-0.34 / -0.38	-0.191	-100.52% (-0.19)
May 07, 2024	2024 (Q1)	1.12 / 0.88	-0.286	409.09% (+1.17)
Mar 20, 2024	2023 (Q4)	0.09 / -0.51	-0.407	-25.06% (-0.10)
Nov 09, 2023	2023 (Q3)	-0.45 / -0.54	1.242	-143.24% (-1.78)
Sep 21, 2023	2023 (Q2)	-0.28 / -0.19	-2.532	92.46% (+2.34)
May 04, 2023	2023 (Q1)	-0.39 / -0.29	-0.489	41.51% (+0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VALN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$6.48	$6.59	+1.70%
Mar 20, 2025	$6.73	$7.25	+7.73%
Nov 07, 2024	$5.59	$5.48	-1.97%
Aug 13, 2024	$6.94	$7.45	+7.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Valneva (VALN) report earnings?

Valneva (VALN) is schdueled to report earning on Aug 12, 2025, TBA (Confirmed).

What is Valneva (VALN) earnings time?

Valneva (VALN) earnings time is at Aug 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VALN EPS forecast?

VALN EPS forecast for the fiscal quarter 2025 (Q2) is -0.32.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing